TARC/CCL17 蛋白, Mouse (70a.a)

TARC/CCL17 Protein, Mouse (70a.a) is the first CC chemokine identified to interact with T cells with high affinity and bind to the CCR4 receptor to mediate inflammation, cancer, and autoimmune related diseases. TARC/CCL17 Protein, Mouse is a recombinant mouse TARC/CCL17(A34-P103) protein expressed by E. coli^[1][2].

CCL17，也称为胸腺和激活调节趋化因子（TARC），是一种通常与2型免疫反应相关的强大趋化因子，其编码基因位于人类16号染色体上。CCL17 可由胸腺细胞和抗原呈递细胞（例如树突状细胞、巨噬细胞和单核细胞）产生，并通过与细胞表面趋化因子受体 CCR4 结合而发挥作用。CCR4 是一种 G 蛋白偶联受体，在 Th2 细胞、皮肤淋巴细胞、皮肤定位 T 细胞和调节性 T 细胞以及成人 T 细胞白血病/淋巴瘤和皮肤 T 细胞淋巴瘤的 T 细胞上表达为趋化因子受体。CCR4 在中枢神经系统 (CNS) 免疫稳态的调节和先天免疫细胞的激活中发挥重要作用。CCL17 在 CCR4 阳性 Th2 淋巴细胞的募集中发挥重要作用，参与嗜酸性粒细胞相关疾病（包括 AA 和 AD）中 Th2 细胞的转运，并可能参与某些 T 细胞淋巴瘤中肿瘤细胞的转运CCL17 也被认为是一种稳态和诱导型神经调节趋化因子，可在稳态条件下维持海马小胶质细胞典型的高度分支形态，并促进小胶质细胞形态对急性 LPS 诱导的神经炎症的适应。CCL17 还与自身免疫性和过敏性疾病相关^[1][2]。

CCL17 (intradermal injection, 0.1-10 µg/mL, 48 h) induces lymphocytic infiltration of the skin by CD4+ lymphocytes in a dose-dependent manner with a maximum response at 1 µg/mL, also induces interleukin-4 mRNA but not interferon-γ mRNA expression in the skin of female BALB/c mice^[3].
CCL17 (intranasally, 10, 30, 90 μg/kg, daily, 3 days) significantly improves neurological function at 72 hours after intracerebral hemorrhage (ICH) at doses of 30 μg/kg and 90 μg/kg, and promotes hematoma resolution and increased CD163 expression on microglia/macrophages by activating the CCR4/ERK/Nrf2 pathway at 30 μg/kg in mice^[4].

1.Full biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 1.0-10 ng/ml.
2.Measured by its ability to enhance Jurkat human lymphoma cells. The ED₅₀ for this effect is 7.464 ng/mL, corresponding to a specific activity is 1.340×10⁵ U/mg.

Mouse

E. coli

Tag Free

F6R5P4 (A34-P103)

20295  [NCBI]

ARATNVGRECCLDYFKGAIPIRKLVSWYKTSVECSRDAIVFLTVQGKLICADPKDKHVKKAIRLVKNPRP

Approximately 7.9-9 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized after extensive dialysis against PBS, pH 7.4 or PBS, pH 7.4, 10% trehalose, 0.02% Tween80.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Julien Catherine, et al. What does elevated TARC/CCL17 expression tell us about eosinophilic disorders? Semin Immunopathol. 2021 Jun;43(3):439-458.  [Content Brief]

  [2]. Jo KM , et al. Thymus and activation-regulated chemokine (TARC)/CCL17 and IgE are associated with elderly asthmatics. Immun Ageing. 2018 May 5;15:13.  [Content Brief]

  [3]. Jan Korbecki, et al. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020 Nov 9;21(21):8412.  [Content Brief]

  [4]. Osabe M, et al. Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation.J Appl Toxicol. 2018 Feb;38(2):274-283.  [Content Brief]

  [5]. Christian Vestergaard, et al. Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Exp Dermatol. 2004 Apr;13(4):265-71.  [Content Brief]

  [6]. Shuixiang Deng, et al. Recombinant CCL17 Enhances Hematoma Resolution and Activation of CCR4/ERK/Nrf2/CD163 Signaling Pathway After Intracerebral Hemorrhage in Mice. Neurotherapeutics. 2020 Oct;17(4):1940-1953.  [Content Brief]